Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

Sodium–glucose cotransporter 2 inhibitors (SGLT2i), a new drug class initially designed and
approved for treatment of diabetes mellitus, have been shown to exert pleiotropic metabolic …

Disease Overview JAK2 unmutated or non‐polycythemia vera (PV) erythrocytosis
encompasses a heterogenous spectrum of hereditary and acquired entities. Diagnosis …

Background: Molecular testing for JAK2 mutations is part of the standard diagnostic workup
for patients with suspected polycythemia vera. We sought to characterize evolving practice …

Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have proven
cardiovascular benefits in patients with type 2 diabetes (T2D). This self-controlled case …

Sažetak Patients with secondary polycythemia (SP) are often referred to hematologists for
investigation of polycythemia vera (PV), a hematological neoplasm characterized by a …

Sodium–glucose co-transporter-2 inhibitors(SGLT2is; canagliflozin, empagliflozin,
dapagliflozin, ertugliflozin and sotagliflozin), also referred to as 'gliflozins', are US Food and …

A total of 52% patients with polycythemia vera have high measured plasma volume. Having
high plasma volume is associated with higher thrombotic risk. Expansion in actual plasma …

Erythrocytosis or polycythemia is defined as an increase in red blood cell concentration
above the age-and sex-specific normal levels. Unlike anemia that is very common in chronic …

A 57-year-old man presented in our outpatient clinic for an extra evaluation because of
increased complaints of dyspnoea and fatigue in the last months. On physical examination …